title: Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses.
abstract: Previous studies have demonstrated that stress may increase prodynorphin gene expression, and kappa opioid agonists suppress drug reward. Therefore, we tested the hypothesis that stress-induced release of endogenous dynorphin may mediate behavioral responses to stress and oppose the rewarding effects of cocaine. C57Bl/6 mice subjected to repeated forced swim testing (FST) using a modified Porsolt procedure at 30 degrees C showed a characteristic stress-induced immobility response and a stress-induced analgesia observed with a tail withdrawal latency assay. Pretreatment with the kappa opioid receptor antagonist nor-binaltorphimine (nor-BNI; 10 mg/kg, i.p.) blocked the stress-induced analgesia and significantly reduced the stress-induced immobility. The nor-BNI sensitivity of the behavioral responses suggests an activation of the kappa opioid receptor by a stress-induced release of dynorphin peptides. Supporting this hypothesis, transgenic mice possessing a disrupted prodynorphin gene showed no increase in immobility or stress-induced analgesia after exposure to repeated FST. Because both stress and the kappa opioid system can modulate the response to drugs of abuse, we tested the effects of forced swim stress on cocaine-conditioned place preference (CPP). FST-exposed mice conditioned with cocaine (15 mg/kg, s.c.) showed significant potentiation of place preference for the drug-paired chamber over the responses of unstressed mice. Surprisingly, nor-BNI pretreatment blocked stress-induced potentiation of cocaine CPP. Consistent with this result, mice lacking the prodynorphin gene did not show a stress-induced potentiation of cocaine CPP, whereas wild-type littermates did. The findings suggest that chronic swim stress may activate the kappa opioid system to produce analgesia, immobility, and potentiation of the acute rewarding properties of cocaine in C57Bl/6 mice.
authors.affiliation: Department of Pharmacology, University of Washington, Seattle, Washington 98195-7280, USA.
authors.forename: Jay P
authors.initials: JP
authors.lastname: McLaughlin
authors.forename: Monica
authors.initials: M
authors.lastname: Marton-Popovici
authors.forename: Charles
authors.initials: C
authors.lastname: Chavkin
mesh_terms: D000698:Analgesia; D000818:Animals; D001522:Behavior, Animal / Q000502:physiology; D003042:Cocaine / Q000494:pharmacology; D004357:Drug Synergism; D004745:Enkephalins / Q000172:deficiency* / Q000235:genetics; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects / Q000235:genetics; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology; D011498:Protein Precursors / Q000172:deficiency* / Q000235:genetics; D011930:Reaction Time; D017473:Receptors, Opioid, kappa / Q000037:antagonists & inhibitors*; D012201:Reward; D013037:Spatial Behavior / Q000187:drug effects; D013312:Stress, Physiological / Q000235:genetics / Q000503:physiopathology*; D013550:Swimming
chemical_list: D004745:Enkephalins; D009292:Narcotic Antagonists; D011498:Protein Precursors; D017473:Receptors, Opioid, kappa; C051844:norbinaltorphimine; D009271:Naltrexone; C033660:preproenkephalin; D003042:Cocaine